Astellas Pharma Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALPMY | D4S.F | CUP.F | REC.VI | BIIB | OFK.F | |
|---|---|---|---|---|---|---|
| Market cap | 28.72B | 31.06B | 65.86B | 11.07B | 37.61B | 14.28B |
| P/E (TTM) | 12.1 | 20.3 | 24.0 | 22.4 | 110.2 | 21.7 |
| Forward P/E | 35.6 | 46.1 | 0.3 | — | 15.6 | — |
| Price/book | 2.3 | 3.1 | 5.6 | 5.1 | 2.0 | 10.2 |
| Dividend yield | 3.09% | 3.57% | 1.93% | 2.67% | — | 1.82% |
| 1-year change | +45.36% | −17.43% | −1.62% | +5.66% | +62.35% | +71.74% |
| Today | −0.62% | +5.64% | +4.33% | 0.00% | +2.22% | +2.99% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All ALPMY news ›Astellas Pharma ADR GAAP EPS of v134.47, revenue of ¥1270.86B; updates FY2027 outlook
Astellas Pharma reports 1H EPS of ¥134.47 and revenue up 23.4% YoY to ¥1,270.86B. - Astellas Pharma ADR press release (ALPMY): 1H GAAP EPS of ¥134.47. More on Astellas Pharma ADR
Astellas Pharma (OTCMKTS:ALPMY) Posts Earnings Results, Misses Expectations By $0.06 EPS
Posted by Danessa Lincoln on Nov 4th, 2026 Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’…
Astellas Pharma Inc. 2027 Q2 - Results - Earnings Call Presentation
2026-11-04. The following slide deck was published by Astellas Pharma Inc. The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2027 Q2 earnings call.
News from Astellas Pharma Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Astellas Pharma Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Oct 06, 2026, 19:30…
Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact
Albany New York October 22 2026 As per DelveInsight s assessment globally Ovarian Cancer pipeline constitutes 180 key companies continuously working towards developing 200 Ovarian Cancer treatment therapies analysis of Clinical Trials…
Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) and Bristol Myers Squibb (NYSE:BMY – Get Free Report) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of…
Astellas Pharma Adopts Patient-Centric Strategy to Offset Patent Expirations
Astellas Pharma CEO Naoki Okamura has outlined a new corporate strategy centered on a “patient axis” operating model, an expanded portfolio of strategic brands, and the development of new scientific technologies to drive future growth. The…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- defenseworld.net1
- geneonline.com1
- pharmexec.com1
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.